Editorial
doi: 10.1097/01.CCM.0000105423.06091.8E.
Mediator modulation therapy of severe sepsis and septic shock: does it work?
- PMID: 14707593
- DOI: 10.1097/01.CCM.0000105423.06091.8E
Item in Clipboard
Editorial
Mediator modulation therapy of severe sepsis and septic shock: does it work?
Crit Care Med.
2004 Jan.
No abstract available
Comment on
-
Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).Crit Care Med. 2004 Jan;32(1):1-12. doi: 10.1097/01.CCM.0000105118.66983.19. Crit Care Med. 2004. PMID: 14707554 Clinical Trial.
-
Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).Crit Care Med. 2004 Jan;32(1):13-20. doi: 10.1097/01.CCM.0000104209.07273.FC. Crit Care Med. 2004. PMID: 14707555 Clinical Trial.
-
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.Crit Care Med. 2004 Jan;32(1):21-30. doi: 10.1097/01.CCM.0000105581.01815.C6. Crit Care Med. 2004. PMID: 14707556 Clinical Trial.
Similar articles
-
A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study.Crit Care Med. 2010 Aug;38(8):1651-64. doi: 10.1097/CCM.0b013e3181e96b91. Crit Care Med. 2010. PMID: 20562695 Review.
-
Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).Crit Care Med. 2004 Jan;32(1):1-12. doi: 10.1097/01.CCM.0000105118.66983.19. Crit Care Med. 2004. PMID: 14707554 Clinical Trial.
-
Profiling pediatric sepsis.Crit Care Med. 2009 May;37(5):1795-6. doi: 10.1097/CCM.0b013e3181a1a220. Crit Care Med. 2009. PMID: 19373046 No abstract available.
-
Corticosteroids and the original vasopressin and septic shock trial subgroups.Crit Care Med. 2010 Jan;38(1):338; authore reply 338-9. doi: 10.1097/CCM.0b013e3181bc7ab8. Crit Care Med. 2010. PMID: 20023496 No abstract available.
-
Severe sepsis, coagulation, and fibrinolysis: dead end or one way?Crit Care Med. 2012 Sep;40(9):2704-8. doi: 10.1097/CCM.0b013e318258ff30. Crit Care Med. 2012. PMID: 22732284 Review.
Cited by
-
Oncology Drug Repurposing for Sepsis Treatment.Biomedicines. 2022 Apr 17;10(4):921. doi: 10.3390/biomedicines10040921. Biomedicines. 2022. PMID: 35453671 Free PMC article. Review.
-
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems.PLoS One. 2013 Aug 28;8(8):e72155. doi: 10.1371/journal.pone.0072155. eCollection 2013. PLoS One. 2013. PMID: 24015214 Free PMC article.
-
Trichinella spiralis excretory-secretory products protect against polymicrobial sepsis by suppressing MyD88 via mannose receptor.Biomed Res Int. 2014;2014:898646. doi: 10.1155/2014/898646. Epub 2014 Jun 26. Biomed Res Int. 2014. PMID: 25054155 Free PMC article.
-
Chitohexaose activates macrophages by alternate pathway through TLR4 and blocks endotoxemia.PLoS Pathog. 2012;8(5):e1002717. doi: 10.1371/journal.ppat.1002717. Epub 2012 May 24. PLoS Pathog. 2012. PMID: 22654663 Free PMC article.
-
Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials.Acad Emerg Med. 2008 May;15(5):399-413. doi: 10.1111/j.1553-2712.2008.00109.x. Acad Emerg Med. 2008. PMID: 18439194 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
